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ABSTRACT
Background and objectives Interaction of bacteria with
the immune system within the intestinal mucosa plays
a key role in the pathogenesis of inﬂammatory bowel
disease (IBD). The aim of the current study was to
develop a ﬂuorescein-aided confocal laser
endomicroscopy (CLE) method to visualise
intramucosal enteric bacteria in vivo and to determine
the involved mucosal area in the colon and ileum
in patients with ulcerative colitis (UC) and Crohn’s
disease (CD).
Methods Initially, E coli strains expressing enhanced
green ﬂuorescent protein (pEGFP) were
endomicroscopically imaged in mice. In addition, ex vivo
and in vivo imaging of ﬂuorescent human enteric bacteria
was performed to specify the distinct endomicroscopic
appearance of enteral bacteria. Targeted mucosal
biopsies towards endomicroscopic identiﬁable
intramucosal bacteria and negative mucosal areas were
prospectively obtained during colonoscopy and
correlated with bench-top ﬂuorescence
microscopy (FISH) to prove the endomicroscopic
visualisation of intramucosal bacteria. Finally,
a retrospective analysis as well as a prospective study
was performed in patients with UC and CD to conﬁrm
the presence and distribution of intramucosal bacteria
within the gut.
Results Confocal endomicroscopy was able to
identify intramucosal pEGFP E coli in mice and strains of
enteric microﬂora in the mucosa of humans. Using FISH
as the gold standard, evaluation of 21 patients showed
that CLE had a sensitivity of 89% and speciﬁcity of 100%
to identify intramucosal bacteria. In a retrospective
study, 113 patients with CD and UC had intramucosal
bacteria signiﬁcantly more often than 50 control
patients (66% vs 60% vs 14%, p<0.001). This
result was conﬁrmed in a prospective study in which
10 patients with CD and 10 with UC had
a signiﬁcantly wider distribution of involvement with
intramucosal bacteria in the colon and terminal ileum
compared with 10 controls (85.2% vs 75.9% vs 16.8%,
p<0.0001).
Conclusions CLE is a new tool that can image
intramucosal bacteria in vivo in patients with IBD.
Intramucosal bacteria are found more frequently and
with a wider distribution in patients with IBD than in
patients with a normal intestine.
INTRODUCTION
The aetiology of inﬂammatory bowel disease (IBD)
is still incompletely understood, but the enteric
ﬂora is believed to play an essential role in its
pathogenesis.
1e6 IBD does not develop in geneti-
cally engineered murine models of colitis in a germ-
free environment but is triggered when commensal
bacteria are introduced into the intestine.
7e9
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Signiﬁcance of this study
What is already known about this subject?
< Enteric bacteria play an important role in the
pathogenesis of inﬂammatory bowel disease
(IBD)
< Intramucosal bacteria have been identiﬁed in
patients with IBD by a variety of techniques
involving mucosal biopsy
< Confocal endomicroscopy can image bacteria on
the mucosal surface but has never been reported
to identify bacteria with the gut mucosa
What are the new ﬁndings?
< Confocal laser endomicroscopy (CLE) using
intravenous ﬂuorescein as a contrast agent
can detect bacteria within the gut mucosa
< Endogenous bacteria seen with CLE have the
same appearance as exogenously applied
ﬂuorescent bacteria
< Using ﬂuorescence in situ hybridisation (FISH)
as a gold standard, CLE detects bacteria with
a sensitivity of 89% and a speciﬁcity of 100%
< A signiﬁcantly greater proportion of patients
with Crohn’s disease and ulcerative colitis have
intramucosal bacteria than patients with
a healthy intestine
< Intramucosal bacteria also have a more extensive
distribution within the intestine of patients with IBD
How might it impact on clinical practice in the
foreseeable future?
< This new endoscopic technique enables the
rapid identiﬁcation of patients with intramucosal
bacteria and will be a valuable tool in the
elucidation of the pathogenesis of IBD and the
development of new clinical algorithms
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EndoscopyMoreover, diversion ileostomy can prevent chronic inﬂammation
in patients with active Crohn’s disease (CD) whereas reinfusion
of stool into the bypassed segments of the intestine results in
a rapid recurrence of the disease.
10 11 Immunological studies
have also stressed that the majority of patients with IBD
develop serological and T cell responses to their own enteric
ﬂora.
12 13 Further evidence implicating the importance of enteric
ﬂora in the perpetuation of IBD is that treatment with antibi-
otics and probiotics has been found to be transiently beneﬁcial
and can be used for induction and maintenance of remission in
IBD.
14e16
Bacterial products and genes have previously been demon-
strated within or attached to the intestinal mucosa of patients
with IBD using a variety of techniques including bacterial
culture, PCR, electron microscopy or immunochemistry.
17e19
However, sampling of the intestinal ﬂora with mucosal biopsies
disrupts the integrity and structural organisation of the mucosal
architecture, preventing determination of the exact location of
bacteria within the mucosa. Thus, it has not been possible
previously to observe the interaction between bacteria and the
mucosal layer in patients with IBD or healthy individuals in
vivo.
Recently, a miniaturised confocal microscope integrated into
the distal tip of a conventional colonoscope has been devel-
oped.
20 Confocal laser endomicroscopy (CLE) is the only tech-
nology that enables microscopic imaging within the mucosal
layer of the gut at subcellular resolution. Although previous case
studies have shown that CLE can identify bacteria on the
mucosal surface during gastroscopy (eg, Helicobacter pylori)
21 and
colonoscopy,
22 no examples of recognition of bacteria within the
wall of the gut have so far been reported.
The aims of the current study were (1) to develop a method to
visualise intramucosal bacteria in animals and humans in vivo
and (2) using ﬂuorescein-aided CLE, to determine the proportion
of patients with ulcerative colitis (UC) and CD with intra-
mucosal bacteria that can be visualised by CLE and to compare
this with patients with normal intestines in a retrospective
preliminary analysis and a prospective study (ﬁgure 1).
MATERIAL AND METHODS
Imaging of ﬂuorescent bacteria in mice
The appearance of enteric bacteria was ﬁrst investigated using
C57BL/6 mice and egfp carrying Escherichia coli. C57BL/6 male
mice were anaesthetised with ketamine (75 mg/kg) and
medotomidine (1 mg/kg) intraperitoneally. Surgery was carried
out to exteriorise a segment of small intestine 2 cm in length as
previously described.
23 The epithelial cells were stained with
topically applied acriﬂavine hydrochloride (3.85 mM) (Sigma,
Australia) and imaged with a rigid confocal mini-microscope
(Optiscan Five 1, Melbourne, Australia) as previously
described.
24 Excitation of laser light was at 488 nm and emission
was greater than 515 nm. Adherent and invasive E coli HM427,
transformed with a plasmid carrying the egfp gene (expression
of enhanced green ﬂuorescent protein, pEGFP; BD Biosciences
Clontech, Mountain View, USA) without alteration of strain-
speciﬁc characteristics such as the ability to adhere to human
intestinal epithelial cells
25 and to replicate inside murine
macrophages,
26 were placed at a concentration of 4310
8
on the luminal surface of the exteriorised intestine for 2 h prior
to imaging. Representative images of intramucosal E coli
were obtained varying the imaging plane depth of the laser
system up to 50 mm from the surface of the intestinal mucosa
(see ﬁgure 2).
Ex vivo and in vivo imaging of ﬂuorescent human enteric
bacteria
Ten ml of stool ﬂuids were aspirated in ﬁve patients during
ongoing colonoscopy. Three ml of ﬂuorescein 10% (Novartis
Pharma, France) were added and the solution was spun centri-
fuged (4000 rev/min, 10 min, 378C). The supernatant was
discarded and 0.1 g of the pellet was further diluted with 20 ml
isotonic saline. This solution was reinjected via the working
channel of the confocal colonoscope onto the mucosal surface of
the same patient from which the stool was harvested. The
whole procedure from aspiration to reinjection took
Figure 1 Study design. FISH, ﬂuorescence in situ hybridisation; UC,
ulcerative colitis.
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Endoscopyapproximately 20 min and was always performed in a single day.
Confocal imaging of the luminal content and the surface of the
colonic mucosa was performed to visualise the ﬂuorescent
bacteria. Confocal imaging in the lumen, at the mucosal surface
and within deeper parts of the mucosa was performed to iden-
tify bacterial translocation. ImageJ Version 1.41 (http://www.
rsbweb.nih.gov/ij/) was used to measure the diameter of the
bacteria.
Fluorescence in situ hybridisation of intramucosal bacteria in
humans
Fluorescence in situ hybridisation (FISH) was performed
prospectively on biopsies from different areas (once in the right
and left colon) of the colon in 21 patients at 26 sites (4 controls,
13 patients with UC, 3 with CD and 1 with IC; ﬁgure 3). Sites
were selected for targeted biopsies on the basis that endomi-
croscopic images of the sites either did or did not show bacteria.
FISH of bacterial rRNA on glass slides was performed as previ-
ously described.
27 In brief, biopsy specimens were immediately
snap frozen in liquid nitrogen and slides with cryosections were
ﬁxed in paraformaldehyde and washed in phosphate buffered
saline. The universal eubacterial oligonucleotide probe EUB-338
(GCT GCC TCC CGT AGG AGT) and the control probe
NONEUB-338 (CGA CGG AGG GCA TCC TCA) complemen-
tary to EUB-338 to exclude non-speciﬁc binding of the probes
were synthesised and 5-prime labelled with Cy3 (Metabion,
Planegg-Martinsried, Germany). Cryosections were incubated
with 25 ng of each oligonucleotide in 50 ml of hybridisation
buffer (containing 20% formamide) for 90 min at 468C before
washing with the same stringency. Nuclear counterstaining was
performed with DAPI (100 mg/ml, Vector Laboratories, Burlin-
game, California, USA) for 5 min at 48C.
In vivo recognition and characterisation of intramucosal bacteria
in humans
Retrospective study
We analysed retrospectively the confocal database of the Inter-
disciplinary Endoscopy Unit of the University of Mainz where
all patient characteristics, endoscopic images and endomicro-
scopic images are stored. We identiﬁed all patients examined
between July 2003 and February 2007 who presented with UC
or CD based on serological, clinical, endoscopic and histological
criteria. Only patients in clinical remission were selected
(patients with CD had a CDAI <150
28 and patients with UC
had a Lichtiger score of <9),
29 and at least three optical sites
within the colon or ileum outside from visible lesions had to
be endomicroscopically investigated. Patients with screening
colonoscopy who had not suffered from diarrhoea for at least
2 months before colonoscopy served as controls. The presence or
absence of bacteria in the colon was assessed in every optical
biopsy (set of confocal images per site) by two blinded investi-
gators. Bacteria were identiﬁed on the basis of their size and
Figure 2 (A, B) Validation of
appearances of intramucosal bacteria at
confocal endomicroscopy. Fluorescent
bacteria on the apical surface of the
surface and invading mouse small
intestinal epithelium. E coli (43108)
were applied onto the luminal surface
for 2 h prior to imaging with an Optiscan
FIVE-1 probe. Epithelial cells are labelled
with 3.85 mm acriﬂavine. The nuclei are
brightly stained (blue arrow). Arrows
indicate labelled bacteria on the surface
(orange) and within villous epithelial
cells (white). Two mice were imaged to
obtain representative images of
intramucosal bacteria.
Figure 3 Intramucosal bacteria in
human colon identiﬁed at confocal laser
endomicroscopy and ﬂuorescence in
situ hybridisation (FISH). (A)
Fluorescent intramucosal bacteria within
the lamina propria can readily be
identiﬁed using ﬂuorescein-aided
endomicroscopy. Single crypts are
shown with their characteristic round
appearance (blue arrow). Single bacteria
as well as clustered bacteria (orange
arrow) can be identiﬁed within the
lamina propria between two crypts
(pericryptal space). (B) FISH testing
conﬁrmed the presence of intramucosal
bacteria due to the bright red
ﬂuorescence. The nuclei and RNA are
shown in blue.
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Endoscopyshape (cylindrical, round or spherical; size range 1e2 mm) as
speciﬁed in previous animal and human experiments. Bacteria
were counted within a distinct ﬁeld of view (60360 mm) which
was centred over the highest amount of ﬂuorescence bacterial
signal. The amount was judged as follows: no bacteria visible,
single bacteria visible, up to 30 bacteria visible, clustered bacteria
visible.
Prospective study
A prospective pilot study was performed on 30 consecutive
patients who presented at a single centre (Interdisciplinary
Endoscopy Unit of University of Mainz) for colonoscopy
because of CD, UC or screening colonoscopy (controls). The
study was approved by the local ethical committee. Inclusion
criteria were clinically and histologically veriﬁed CD or UC in
clinical remission. Exclusion criteria were an acute ﬂare with
bloody diarrhoea, diarrhoea with >4 bowel movements per day,
impaired coagulation parameters (Quick <50%; pTT >50 s),
impaired renal function (creatinine >1.2 mg/dl), allergy to
ﬂuorescein, known gastrointestinal cancer, known stenosis of
the ileum or colon, colonic or ileal surgery. Patients were
excluded from further analysis if the terminal ileum could not be
reached endoscopically or the bowel preparation was insufﬁcient
(dropout criteria).
Confocal endomicroscopy was performed as described previ-
ously using intravenous ﬂuorescein as a contrast agent.
20 The
colonic mucosa and terminal ileum were examined systemati-
cally every 10 cm and 10e20 endomicroscopic images from the
surface to the deeper parts of the mucosa were obtained from
each site.
Intramucosal bacteria were quantiﬁed using a method devel-
oped as a result of our experience from the retrospective study
and FISH testing. Bacteria within the intestinal lumen were not
counted. The abundance of intramucosal bacteria was judged
based on the affected area within the endomicroscopic ﬁeld of
view (4753475 mm). Each image was divided into four quad-
rants and each quadrant was scored for the presence or absence
of bacteria. If no quadrant contained bacteria the image was
scored as ‘no bacteria’, if only one quadrant contained bacteria
the image was scored as ‘scanty bacteria’, and if more than one
quadrant contained bacteria it was scored as ‘abundant bacteria’.
All images within one optical site were evaluated and the
most severe changes were noted. The presence of cellular inﬁl-
trates within the lamina propria and crypt distortion based on
the Mainz criteria
20 were also evaluated for each optical site.
The conventional endoscopic assessment of macroscopic signs of
inﬂammation was also recorded at each site. Endomicroscopic
images were evaluated by an investigator blinded to the history
and the endoscopic results of the patients.
Statistical testing
Absolute and relative frequencies were calculated for qualitative
variables in all patient groups; t tests and one-way ANOVAwere
used to analyse dependencies within two or three patient
populations. Regression and multivariate analysis were addi-
tionally performed. Statistics were computed using SAS Release
6.08 (SAS Institute Inc).
RESULTS
Imaging of ﬂuorescent bacteria in mice
Our ﬁrst goal was to determine the appearance at confocal
endomicroscopy of bacteria on the surface of the intestinal
mucosa and also within the epithelial layer. We ﬁrst determined
the appearance of ﬂuorescent E coli when applied to the mucosal
surface of the small intestine of anaesthetised mice. E coli was
chosen as an example of intestinal bacteria that are known to
invade the intestinal mucosa. We used a strain that has been
engineered to express pEGFP.
25 26 Imaging was undertaken with
a rigid confocal mini-microscope (Optiscan Five 1). This
instrument has the same confocal scanning technology as the
Pentax confocal endomicroscope with which we imaged
patients. Thus, the two instruments have identical confocal
resolution, depth of plane of focus and image display. Fluores-
cent E coli could be identiﬁed with the mini-microscope in the
lumen, on the apical surface of the epithelial cell layer as well as
invading into deeper parts of the mucosal layer (ﬁgure 2). They
had the appearance of intensely ﬂuorescent spots approximately
1e2 mm in diameter that could easily be seen against the less
intense ﬂuorescence of the acriﬂavine-stained epithelial and
subepithelial cells (ﬁgure 2). For comparison, intestinal epithelial
cells are approximately 10 mm wide.
Bacteria from the human colon were labelled ex vivo with
acriﬂavine and reinstilled into the same patients onto the
mucosal surface to establish the typical appearance of bacteria in
vivo with confocal endomicroscopy. As shown in ﬁgure 4, the
bacteria appeared as bright white spots or rods, often in small
colonies, similar in appearance to the animal experiments
described above.
Figure 4 Appearance of human faecal
bacteria labelled ex vivo. Bacteria were
harvested from the human colon at
colonoscopy, labelled as described in
the Materials and Methods section and
reinstilled into the human colon. Images
were then obtained at confocal laser
endomicroscopy. (A) Image of human
terminal ileum showing bacteria labelled
ex vivo that have entered the epithelial
cells (orange arrow). (B) Magniﬁed
image.
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EndoscopyFluorescence in situ hybridisation of intramucosal bacteria in
humans
To image intestinal bacteria in humans by confocal endomicro-
scopy, we reasoned that intravenous administration of ﬂuores-
cein to patients might label intramucosal bacteria since we have
previously shown that intravenous ﬂuorescein can leach out of
blood vessels and label intestinal epithelial cells.
20 Using this
technique, we found that distinct structures were labelled by
ﬂuorescein and appeared within epithelial cells or the lamina
propria of the mucosa. These structures strongly resembled
intraepithelial and intramucosal bacteria, having the same
appearance as pEGFP-expressing bacteria applied to the surface
of murine small intestine and human bacteria labelled ex vivo
(ﬁgures 3 and 4). This suggests that sufﬁcient ﬂuorescein is taken
up to label at least a proportion of bacteria in the lamina propria
and within epithelial cells.
FISH was used to provide additional validation of the
appearance of the bacteria at confocal endomicroscopy, using
a universal eubacterial oligonucleotide probe EUB-338 on
targeted biopsies of areas we had imaged with confocal endo-
microscopy in 21 patients. This probe identiﬁes RNA that is
speciﬁc to all bacterial species but does not recognise mamma-
lian RNA. Twenty-six sites in 21 patients were selected
prospectively for targeted biopsies within 0.5 mm of the site of
endomicroscopic images that either did or did not show bacteria.
In 24 out of 26 sites, FISH conﬁrmed the presence or absence of
bacteria in all analysed specimens as predicted by endomicro-
scopy (ﬁgure 3). The sensitivity was 89% (16/18) and speciﬁcity
was 100% (8/8) for the presence of intramucosal bacteria
detected with CLE using FISH as the gold standard. The positive
predictive value was 100% (16/16), the negative predictive value
was 80% (8/10) and the accuracy was 92.3% (24/26). Thus, there
is a strong correlation between the universal bacterial signal
from FISH analysis and the presence or absence of bacteria as
identiﬁed by CLE. However, it was not possible to identify the
bacterial species by either technique.
Frequency of the presence or absence of intramucosal bacteria
in humans with and without IBD: retrospective and prospective
studies
We initially undertook a preliminary retrospective study of the
frequency of the presence of intramucosal bacteria in 50 control
patients, 84 with UC and 29 with CD using images (27062
images analysed) from our database. We found a higher
frequency of endomicroscopic identiﬁable intramucosal bacteria
in patients with UC (60%) and CD (66%) compared with
control patients (14%, p<0.01). In both the CD and UC groups
there was no difference in mean Baron score or Rutgeerts’ score
between patients with or without bacteria (CD: 1.2661.15 vs
1.2661.13, p¼0.89; UC: 2.1560.95 vs 1.8061.30, p¼0.24).
We have previously shown that there is increased capillary
leakage of ﬂuorescein at sites of active inﬂammation. This raises
the possibility that the increased numbers of bacteria seen in
patients with IBD is an artefact resulting from more ﬂuorescein
being available for bacterial uptake, although we mainly exam-
inedpatientsinclinicalandendoscopicremission.Toevaluatethis
possibility we determined the average pixel intensity of bacteria
and compared this with the average pixel intensity of a 535 pixel
region of interest, cells 5 pixels distant from the bacterium. No
difference in the pixel intensity of cells or bacteria was found in
controls, patients with UC or with CD (ﬁgure 5A). We therefore
concludethattheincreasedabundanceofbacteriaseeninpatients
with IBD is not an artefact of different concentrations of ﬂuo-
rescein available for bacterial uptake within the tissue.
Prospective study
Based on our FISH and animal studies, we devised a simple
scoring system (visible bacteria per quadrant) for a prospective
and systematic study of the frequency of intramucosal bacteria
in patients with IBD compared with controls. This scoring
system and the systematic endomicroscopic image collection
every 10 cm took account of the substantial heterogeneity of the
frequency of intramucosal bacteria observed in our retrospective
study.
Atotal of6634images (2622CD,2462UC,1550controls)were
analysed in 243optical sites. There werenosigniﬁcantdifferences
betweenthethreedifferent patientgroups inage, gender,amount
of sedation or average number of images per site. Representative
images of intramucosal bacteria from the colon and terminal
ileum are shown in ﬁgure 5B. All patients with CD (10/10) and
UC (10/10) had intramucosal bacteria whereas only 5/10 control
patients were positive. We also found a statistically wider
distribution of intramucosal bacteria in the colon and terminal
ileum in patients with CD or UC with bacteria compared with
controls (percentage of positive optical sites 85.2% vs 75.9% vs
16.8%, p<0.0001; ﬁgure 6 and table 1). A consistent increase in
bacteria in patients with IBD compared with controls was found
at each 10 cm segment imaged including the terminal ileum
(ﬁgure 6). In patients with CD the areas where abundant bacteria
were most frequent were the caecum and terminal ileum
whereas,inpatientswithUC,abundantbacteriawerefrequentin
both the rectum and terminal ileum. The distribution of the
bacteria in control patients was patchy compared with patients
with IBD. There was no correlation between the presence of
intramucosal bacteria and macroscopic inﬂammation visible at
endoscopy, crypt distortion and the presence of inﬂammatory
inﬁltrate. However, there was one signiﬁcant correlation in
patientswithCDonly;thosewithCDwithleakageofﬂuorescein
into the lumen had signiﬁcantly more intramucosal bacteria
than patients with CD without leakage (p¼0.019).
DISCUSSION
In this study we have developed a new confocal endomicro-
scopic technique for the identiﬁcation of patients with colonic
or ileal intramucosal bacteria. Using endomicroscopy, we found
that intramucosal bacteria are found more frequently in patients
with colitis than in patients with a normal colon or terminal
ileum. An important feature of confocal endomicroscopy
compared with magnifying endoscopy is that, although both
technologies can identify surface structures, only confocal
endomicroscopy can identify bacteria within the epithelial cells
and lamina propria.
Our technique depends on intravenous ﬂuorescein which
leaks out of mucosal capillaries and stains intramucosal bacteria
which take up ﬂuorescein more avidly than surrounding struc-
tures. We have reported previously that there is increased ﬂuo-
rescein leakage in the inﬂamed intestine.
30 This raises the
possibility that ﬂuorescein might be available within the tissue
for uptake by bacteria which might lead to more bacteria
becoming visible. We found in practice that this was not the
case. As shown in ﬁgure 5A, there was no difference in ﬂuorescent
intensity of ﬂuorescein in cells beside bacteria (ie, at a distance of
5 pixels). We found that, when there was substantial ﬂuorescein
capillary leakage causing a high ﬂuorescein signal within the
epithelial cells, bacteria were not clearly seen. This is because our
technique depends on a high contrast in ﬂuorescein ﬂuorescence
from the bacteria compared with their cellular environment.
Our technique therefore will tend to underestimate the presence
30 Gut 2011;60:26e33. doi:10.1136/gut.2010.213264
Endoscopyof bacteria in areas of intense inﬂammation. It is thus highly
unlikely that the increased prevalence of intramucosal bacteria
we observed in patients with IBD is an artefact of capillary
leakage of ﬂuorescein. It should be noted that intravenous ﬂuo-
rescein differs from acriﬂavine applied to the surface of the
intestine which stains luminal bacteria such as H pylori directly.
19
Figure 5 Intramucosal bacteria in control patients, patients with ulcerative colitis (UC) and patients with Crohn’s disease. (A) Average pixel intensity
of bacteria and a 535 pixel region of interest 5 pixels away from the bacterium. The number of bacteria and patients examined was as follows: control
patients: 54 bacteria from 9 patients; UC: 54 bacteria from 5 patients; Crohn’s disease: 52 bacteria from 5 patients. As bacteria are less abundant in
control patients, images from more patients had to be analysed to accumulate sufﬁcient bacteria. (B) Examples of intramucosal bacteria from the small
intestine and colon of controls, patients with UC and patients with Crohn’s disease. An enlarged image of the bacteria within the small square is shown
at the lower left of each image. TI, terminal ileum.
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EndoscopyTwo lines of evidence validate our technique: E coli expressing
pEGFP appear as ﬂuorescent spots 1e2 mm in diameter both on
the apical surface of epithelial cells and within epithelial cells of
mouse intestine (ﬁgure 2). The rigid confocal endomicroscope
(Optiscan) used for these studies contains the same scanning
head as the ﬂexible endomicroscope embedded within an endo-
scope (Pentax) so images from the mouse are the precise
equivalent to those from human endomicroscopy. Intramucosal
bacteria imaged by confocal endomicroscopy look similar to
pEGFP-labelled E coli. Furthermore, faecal bacteria harvested
from patients and stained with acriﬂavine ex vivo also have the
same appearance as intramucosal bacteria seen with confocal
endomicroscopy (ﬁgure 4). Second, we show that CLE identiﬁes
intramucosal bacteria with a sensitivity of 89% and a speciﬁcity
of 100% using FISH analysis of biopsies of areas close to
(<5 mm) the confocal images of the mucosa. While there are
a variety of artefacts and non-speciﬁc appearances on confocal
endomicroscopy, there are very few that cause spots 1e2 mmi n
diameter within the epithelial layer. These ﬁndings stress the
advantage of using CLE compared with other available tech-
nologies because bacteria within the lamina propria could only
be observed rarely by combining untargeted biopsies and
FISH analysis
36 or comparable other techniques like PCR or
culture.
17 31e35 Fluorescein-guided endomicroscopy could not
only localise intramucosal bacteria but also enabled us to iden-
tify single bacteria and bacterial clusters within the distinct
endomicroscopic ﬁeld of view. In addition, imaging with CLE is
not prone to artefacts secondary to ﬁxation which might
interfere with bacterial visualisation. Since CLE does not disrupt
the integrity of the epithelial barrier, bacterial contamination of
the specimens (eg, by luminal contents) as occurs when taking
a biopsy does not occur.
Our study does not attempt to identify individual species or
classes of bacteria as endomicroscopy is only able to image the
general shape of the bacteria. Bacteria that are unable to take up
ﬂuorescein are not imaged with this technique.
33 Bacteria in the
intestinal lumen can also be imaged, but only if there is a loss of
intestinal barrier allowing ﬂuorescein to leak into the lumen. We
have shown previously that cell shedding induced by the
inﬂammatory mediator tumour necrosis factor a (TNFa) can
cause a loss of barrier function and is likely to occur in IBD.
24
Nonetheless, labelling of bacteria within the intestinal mucosa
identiﬁes at least the majority of bacteria present as we found
that CLE has a sensitivity of 89% for detecting intramucosal
bacteria using FISH as the gold standard.
In our preliminary retrospective study we found that more
patients with colitis harbour intramucosal bacteria than patients
with a healthy terminal ileum and colon. Furthermore, our
systematic prospective study clearly showed that more patients
with IBD had intramucosal bacteria in the colon and terminal
ileum than controls and that the bacteria were more widely
distributed (table 1, ﬁgure 6). These results point to defects in
the defence mechanisms against bacterial invasion in IBD. We
did not ﬁnd any correlation between the presence of intra-
mucosal bacteria and areas of macroscopic inﬂammation,
corroborating previous studies.
17 31 32 36e41 This may partly be
due to bacteria not being clearly seen in areas of inﬂammation as
discussed above, but may also be because there are intervening
pathogenic mechanisms between bacterial invasion and the
triggering of an inﬂammatory response. Our observation that
intramucosal bacteria can be found in healthy patientsdalbeit
less frequentlydlends support to the idea that the presence of
intramucosal bacteria, potentially indicating an intestinal barrier
defect,
42 43 is insufﬁcient to trigger an inﬂammatory response. A
further difference between patients with IBD and controls may
be that their gut microbiota are more prone to invasion.
Our results are in contrast to the results of studies that use
different ex vivo detection technologies.
17 31e35 These latter
found that the number of bacteria on the mucosal surface
increases progressively from self-limiting colitis to UC and from
UC to CD, being two powers higher than those in healthy
controls.
34 Also, Bibiloni et al have shown that the number of
bacteria from biopsies obtained from patients with UC were
twice as high as in samples from patients with CD.
31 Our
technique does not attempt to accurately quantify the bacterial
number as it only has the resolution to distinguish absent,
scanty or abundant bacteria. The marked inter- and intra-patient
heterogeneity in bacterial numbers precludes a more quantita-
tive approach. However, within these constraints, patients with
CD had abundant bacteria more often in the caecum and the
terminal ileum whereas, in patients with UC, the rectum was
mainly affected. This distribution may reﬂect the known
distribution of inﬂammation in these diseases.
In conclusion, these animal and human data clearly show that
bacteria within the intestinal mucosa can be imaged by CLE. We
found that intramucosal bacteria are more common in patients
Figure 6 Increased intramucosal bacteria in patients with inﬂamma-
tory bowel disease. Images were taken systematically at 10 cm
intervals from the anal verge to the terminal ileum and analysed for the
presence of bacteria. The percentage of control patients and patients
with ulcerative colitis (UC) or Crohn’s disease (CD) is plotted at each
10 cm point. At each segment more patients with UC and CD had
intramucosal bacteria than control patients (p<0.0001; 10 patients in
each group).
Table 1 Distribution of endomicroscopically identiﬁed intramucosal
bacteria
Crohn’s
disease
Ulcerative
colitis
Control
group
N1 0 1 0 1 0
Optical sites 79 87 77
Presence of bacteria (% of sites containing intramucosal bacteria)
Colon and ileum 85.2 75.9 16.8
Presence of bacteria (%) per single optical sites (distance from anal verge)
10 cm 62.5 100 11.1
20 cm 85.7 75.0 0.0
30 cm 83.3 75.0 0.0
40 cm 100.0 87.5 20.0
50 cm 77.8 77.8 0.0
60 cm 80.0 70.0 12.5
70 cm 77.8 70.0 50.0
80 cm 90.0 55.6 14.3
90 cm 90.0 75.0 33.3
Ileum 100.0 75.0 20.0
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Endoscopywith UC and CD compared with a patient cohort undergoing
screening colonoscopy with no gastrointestinal symptoms.
Endomicroscopy seems to be superior to other available tech-
nologies because bacteria can be observed in vivo during ongoing
colonoscopy.
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